Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Placebo-and Positive-controlled Crossover Study To Determine The Effect Of Single-dose Pf-06700841 On Qtc Interval In Healthy Volunteers

Trial Profile

A Phase 1, Randomized, Placebo-and Positive-controlled Crossover Study To Determine The Effect Of Single-dose Pf-06700841 On Qtc Interval In Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2018

At a glance

  • Drugs PF 6700841 (Primary)
  • Indications Alopecia areata; Crohn's disease; Inflammatory bowel diseases; Plaque psoriasis; Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 28 Nov 2018 Planned End Date changed from 3 Dec 2018 to 6 Jan 2019.
    • 28 Nov 2018 Planned primary completion date changed from 7 Nov 2018 to 11 Dec 2018.
    • 24 Sep 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top